Claret Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Claret Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$228K	Sell	948 -1,192	-56%	-$261K	0.02%	306
2026 Q1	$405K	Hold	2,140	–	–	0.05%	132
2025 Q4	$364K	Sell	2,140 -5	-0.2%	-$767	0.04%	143
2025 Q3	$283K	Sell	2,145 -30	-1%	-$3.6K	0.03%	174
2025 Q2	$231K	Buy	2,175 +418	+24%	+$45.4K	0.03%	383
2025 Q1	$218K	Buy	1,757 +1	+0.1%	+$130	0.03%	244
2024 Q4	$216K	Buy	+1,756	New	+$207K	0.03%	248
2019 Q4	–	Sell	-1,617	Closed	-$207K	–	206
2019 Q3	$207K	Buy	+1,617	New	+$217K	0.04%	177

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Claret Asset Management's JAZZ Position: Q2 2026 in Review

Claret Asset Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 56% in Q2 2026, selling an estimated $261K and leaving 948 shares worth $228K. The position accounts for 0.02% of the portfolio, ranked #306.

Claret Asset Management first reported a position in JAZZ in Q3 2019 and has held it in 8 quarters since. The position peaked at $405K in Q1 2026. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Claret Asset Management held 948 shares of Jazz Pharmaceuticals worth $228K as of Q2 2026.
Claret Asset Management sold 1,192 Jazz Pharmaceuticals shares in Q2 2026, an estimated $261K.
Jazz Pharmaceuticals made up 0.02% of Claret Asset Management's portfolio in Q2 2026, its #306 holding.
Claret Asset Management first reported a position in Jazz Pharmaceuticals in Q3 2019 and has held it in 8 quarters since.
Claret Asset Management's Jazz Pharmaceuticals position peaked at $405K in Q1 2026.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Claret Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.